Key result
Deflazacort plus perindopril in DMD is linked to ~13% higher LVEF and absent LGE versus deflazacort.
Why the study?
Does the combination of deflazacort and perindopril preserve left ventricular function and prevent myocardial fibrosis in asymptomatic boys with Duchenne muscular dystrophy compared to deflazacort alone?
Cross-Sectional (n=68)
Single-blind
No
Does the combination of deflazacort and perindopril preserve left ventricular function and prevent myocardial fibrosis in asymptomatic boys with Duchenne muscular dystrophy compared to deflazacort alone?
Absolute Event Rate: 69.16% vs 56.08%
p-value: p=<0.001
In asymptomatic boys with Duchenne muscular dystrophy, treatment with both deflazacort and perindopril is associated with preserved left ventricular function and absence of myocardial fibrosis on CMR compared to deflazacort alone.
May support adding perindopril to deflazacort for LV preservation in DMD; hypothesis-generating, needs prospective trials.
BACKGROUND: To evaluate cardiovascular function in boys with Duchenne (DMD) and Becker (BMD) muscular dystrophy, using cardiac magnetic resonance (CMR). METHODS: This is a single point cross sectional study of twenty-four boys with genetically ascertained DMD, and 10 with BMD, aged 10.5 ± 1.5 years (range 9-13), were prospectively evaluated by a 1.5 T system and compared with those of age-sex matched controls. The DMD patients were divided in 2 groups. Group A (N = 12) were under treatment with both deflazacort and perindopril, while Group B (n = 12) were under treatment with deflazacort, only. BMD patients did not take any medication. Biventricular function was assessed using a standard SSFP sequence. Late gadolinium enhancement (LGE) was assessed from T1 images taken 15 min after injection of 0.2 mg/Kg gadolinium DTPA using a 3D-T1-TFE sequence. RESULTS: Group A and BMDs were asymptomatic with normal ECG, 24 h ECG recording and echocardiogram. Group B were asymptomatic but 6/12 had abnormal ECG and mildly impaired LVEF. Their 24 h ECG recording revealed supraventricular and ventricular extrasystoles (all at 12-13 yrs). LV indices in Group A and BMD did not differ from those of controls. However, LV indices in Group B were significantly impaired compared with controls, Group A and BMDs (p < 0.001). An epicardial LGE area = 3 ± 0.5% of LV mass was identified in the posterolateral wall of LV only in 6/12 patients of Group B, but in not in any BMD or Group A. CONCLUSION: Children with either BMD or DMD under treatment with both deflazacort and perindopril present preserved LV function and lack of LGE. However, further large scale multicenter studies are warranted to confirm these data, including further CMR mapping approaches.
No takes yet. Share an insight, caveat, or question.
Mavrogeni et al. (2017) conducted a cross-sectional in Duchenne and Becker muscular dystrophy (n=68). Deflazacort and perindopril vs. Deflazacort alone was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.001). Boys with Duchenne muscular dystrophy treated with both deflazacort and perindopril maintained preserved left ventricular ejection fraction and lacked late gadolinium enhancement, whereas those on deflazacort alone showed significantly impaired left ventricular function (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: